Physician profile
Eduardo Miranda
NPI 1285673012
$35,335.10
in general payments reported to CMS, 2019-2025
86 companies · $8,447 in 2025
The $8,447 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,648 · 2020: $3,160 · 2021: $5,025 · 2022: $4,416 · 2023: $5,111 · 2024: $5,528 · 2025: $8,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Travel and Lodging: $1,534 · Education: $1,231 · Long Term Medical Supply Or Device Loan: $997 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,304.96 |
| Travel and Lodging | $1,533.65 |
| Education | $1,231.00 |
| Long Term Medical Supply Or Device Loan | $997.00 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $2,991.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,936.96 | 2019-2025 | |
| Pfizer INC. | $2,488.09 | 2019-2025 | |
| Janssen Biotech, INC. | $2,053.30 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $1,891.11 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $1,758.58 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $1,657.14 | 2019-2025 | Xtandi, Xospata, Padcev |
| Seagen INC. | $1,463.98 | 2019-2025 | Adcetris, Tukysa, Padcev |
| Amgen INC. | $1,298.90 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Incyte Corporation | $1,208.21 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Celgene Corporation | $866.42 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $844.94 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $839.50 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $824.73 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Eisai INC. | $785.70 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $706.31 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Glaxosmithkline, LLC. | $694.49 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Karyopharm Therapeutics INC. | $535.30 | 2020-2025 | Xpovio |
| Regeneron Healthcare Solutions, INC. | $496.22 | 2020-2025 | Libtayo, Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $469.46 | 2019-2025 | |
| Sobi, INC | $462.77 | 2022-2025 | |
| Exelixis INC. | $443.39 | 2019-2024 | Cabometyx |
| Puma Biotechnology, INC. | $434.71 | 2019-2025 | Nerlynx |
| Aveo Pharmaceuticals, INC. | $418.40 | 2021-2025 | Fotivda |
| Gilead Sciences, INC. | $406.08 | 2021-2025 | Trodelvy |
| Adc Therapeutics America, INC. | $362.59 | 2022-2025 | |
| Array Biopharma INC | $361.54 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $326.73 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Jazz Pharmaceuticals INC. | $288.48 | 2021-2025 | |
| Abbvie INC. | $237.94 | 2019-2025 | |
| Morphosys, US INC. | $234.48 | 2021-2023 | Monjuvi |
| Lilly USA, LLC | $226.61 | 2019-2024 | Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $219.56 | 2021-2025 | Onivyde, Somatuline Depot |
| Pharmaessentia USA Corporation | $212.02 | 2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.97 | 2019-2022 | |
| Beigene USA, INC. | $193.74 | 2020-2025 | Brukinsa |
| Kite Pharma, INC. | $191.47 | 2020-2024 | Yescarta |
| Taiho Oncology, INC. | $184.35 | 2019-2025 | |
| Dova Pharmaceuticals | $171.97 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $156.06 | 2019-2022 | |
| Emd Serono, INC. | $145.78 | 2019-2025 | |
| Daiichi Sankyo INC. | $138.87 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $132.28 | 2024-2025 | Pyrukynd |
| Stemline Therapeutics INC. | $131.12 | 2023-2025 | Orserdu |
| Epizyme, INC. | $116.08 | 2021 | |
| Genmab U.S., INC. | $113.59 | 2024-2025 | Epkinly |
| Janssen Pharmaceuticals, INC | $112.42 | 2019 | |
| Octapharma USA, INC. | $106.86 | 2021-2024 | Octagam Immune Globulin (Human), Panzyga |
| Alexion Pharmaceuticals, INC. | $105.16 | 2022-2025 | Ultomiris, Soliris |
| Sumitomo Pharma America, INC. | $104.49 | 2023-2024 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $96.99 | 2021-2025 | Qinlock, Romvimza |
| Bolton Medical INC | $95.29 | 2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Pharmacosmos Therapeutics INC. | $94.64 | 2021-2024 | Monoferric |
| Tersera Therapeutics LLC | $89.06 | 2024 | Zoladex, Xermelo |
| Geron Corporation | $86.98 | 2024-2025 | Rytelo |
| Foundation Medicine, INC. | $82.62 | 2021-2023 | Foundationone Cdx |
| Spectrum Pharmaceuticals INC. | $82.48 | 2023-2024 | Rolvedon |
| Verastem, INC. | $79.91 | 2019 | |
| Coherus Oncology, INC. | $72.54 | 2020-2022 | |
| Blueprint Medicines Corporation | $71.38 | 2022-2024 | Ayvakit |
| Tactile Systems Technology INC | $67.20 | 2020-2021 | |
| Myovant Sciences INC. | $63.61 | 2021-2022 | |
| Mirati Therapeutics, INC. | $57.39 | 2023-2024 | Krazati |
| Kyowa Kirin, INC. | $54.30 | 2022-2025 | |
| Legend Biotech USA INC. | $48.06 | 2025 | Carvykti |
| Recordati_rare_diseases_inc. | $37.20 | 2024 | Sylvant |
| Caris Mpi, INC. | $37.05 | 2025 | Mi Cancer Seek |
| Melinta Therapeutics, LLC | $34.37 | 2020 | |
| Tempus Ai, INC | $29.72 | 2024 | |
| Immunocore Limited | $25.02 | 2023 | Kimmtrak |
| Teleflex LLC | $24.99 | 2023 | Arrow |
| Azurity Pharmaceuticals, INC. | $23.76 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $23.69 | 2025 | Ogsiveo |
| Cti Biopharma Corp. | $22.73 | 2023 | Vonjo |
| Immunogen, INC. | $21.58 | 2024 | Elahere |
| Mylan Institutional INC. | $21.45 | 2023 | Ogivri, Fulphila |
| Organon LLC | $21.44 | 2021 | |
| Acceleron Pharma, INC. | $21.39 | 2021 | |
| Syndax Pharmaceuticals, INC. | $19.70 | 2025 | |
| Tg Therapeutics, INC. | $18.48 | 2022 | |
| Clovis Oncology, INC. | $14.73 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $13.43 | 2020 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Secura Bio, INC. | $11.30 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,068.30 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.